Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21705352 | 0.91 | PDE5A (0.68) | PDE5A | |
| SCHEMBL21705157 | 0.91 | PDE5A (0.83) | PDE5AHDAC1HDAC6HDAC2 | |
| SCHEMBL21705393 | 0.90 | PDE5A (0.60) | PDE5AHDAC1HDAC6HDAC2 | |
| SCHEMBL21705397 | 0.89 | PDE5A (0.79) | PDE5AHDAC1HDAC6HDAC2 | |
| SCHEMBL21705395 | 0.84 | PDE5A (0.70) | PDE5A | |
| SCHEMBL21682533 | 0.83 | PDE5A (0.95) | PDE5AHDAC1HDAC6HDAC2 | |
| SCHEMBL21682493 | 0.83 | PDE5A (0.83) | PDE5A | |
| SCHEMBL21705156 | 0.82 | PDE5A (0.69) | PDE5A | |
| SCHEMBL21705134 | 0.81 | PDE5A (0.62) | PDE5A | |
| SCHEMBL18539070 | 0.81 | PDE5A (0.63) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2024-07-25 | — | — | US | claimed |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | claimed |
| CN-112566670-A | Nitric oxide releasing phosphodiesterase type 5 inhibitors | 尼科斯股份有限公司 | 2021-03-26 | — | — | CN | claimed |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2024-07-25 | — | — | US | disclosed |
| CN-112566670-A | Nitric oxide releasing phosphodiesterase type 5 inhibitors | 尼科斯股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE6A, PDE3A | PDE5A 1/4885HDAC1 1298/4885HDAC6 1620/4885 |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE3A, PDE6A | PDE5A 1/4885HDAC1 1159/4885HDAC6 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.